Akari Therapeutics (AKTX) Cash from Investing Activities (2014 - 2016)

Akari Therapeutics (AKTX) has 3 years of Cash from Investing Activities data on file, last reported at -$42083.0 in Q1 2016.

• For the quarter ending Q1 2016, Cash from Investing Activities changed N/A year-over-year to -$42083.0; the trailing twelve-month figure through Mar 2016 stood at $1.3 million (changed N/A YoY), and the FY2024 full-year result was $382000.0, changed N/A from the prior year.
• Cash from Investing Activities retreated to -$42083.0 in Q1 2016, from -$18779.0 in the prior quarter.
• In the past five years, Cash from Investing Activities ranged from a high of $1.4 million in Q3 2015 to a low of -$142000.0 in Q2 2014.
• A 3-year average of $269943.0 and a median of -$18779.0 in 2015 frame the typical range for Cash from Investing Activities.
• Peak annual rise in Cash from Investing Activities reached 893.36% in 2015, while the deepest fall reached 893.36% in 2015.
• Tracing AKTX's Cash from Investing Activities over 3 years: stood at $142000.0 in 2014, then sank by 113.22% to -$18779.0 in 2015, then slumped by 124.1% to -$42083.0 in 2016.
• Business Quant data shows AKTX's Cash from Investing Activities at -$42083.0 in Q1 2016, -$18779.0 in Q4 2015, and $1.4 million in Q3 2015.